Zenocutuzumab-zbco Drug Asset Due Diligence Report 2026

This Zenocutuzumab-zbco Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Zenocutuzumab-zbco can convert its Bispecific antibody profile and HER2 x HER3 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Zenocutuzumab-zbco (query alias: zenocutuzumab)
Modality / target	Bispecific antibody; HER2 x HER3; HER2 antagonists, HER3 antagonists
Highest global status	Approved
Originator	Merus NV
Active developers	Partner Therapeutics, Inc., Merus NV

The MCP disease footprint includes NRG1 gene fusion cholangiocarcinoma, Adenocarcinoma of pancreas with NRG1 fusion, NRG1 Fusion Positive non-small cell lung cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT02912949	Phase 2	Active, not recruiting	250	Objective overall response rate (ORR) as per local investigator's assessment
NCT03321981	Phase 2	Completed	105	Clinical Benefit Rate at 24 Weeks
NCT05588609	Phase 2	Terminated	13	Group A: Evaluate efficacy of zenocutuzumab in combination with afatinib in terms of response.

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Continued zenocutuzumab treatment beyond progression in patients with NRG1+ pancreatic cancer and cholangiocarcinoma: Analysis from the phase 2 eNRGy trial.

Phase 2; n=17; evaluation: Positive. Reported fields: AE(Grade 3/4) = 12.0 %

Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Phase 2; n=204; evaluation: Positive. Reported fields: ORR = 29 % ( 20 - 39); ORR = 30 % ( 23 - 37); ORR = 42 % ( 25 - 59)

FDA-Approved Drugs-BIZENGRI-CLINICAL STUDIES(II)

Phase 2; n=30; evaluation: Positive. Reported fields: ORR = 67 % (95%CI, 9 - 99); ORR = 33 % (95%CI, 0.8 - 91); ORR = 50 % (95%CI, 23 - 77)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Zenocutuzumab-zbco addresses NRG1 gene fusion cholangiocarcinoma, Adenocarcinoma of pancreas with NRG1 fusion, NRG1 Fusion Positive non-small cell lung cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Bispecific antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2024-12-02	Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer	NDA/BLA	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO